Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home News room Press releases 2006
Press releases

2006

13/12/2006
ABLYNX identifies novel nanobodies® achieving first milestone in procter & gamble collaboration

NL 

06/11/2006
Ablynx enters into a research and license agreement with Wyeth

NL     FR

16/10/2006
Ablynx expands and relocates to new facilities

NL     FR

23/08/2006
ABLYNX completes €40M (~US$50M) series c financing - one of the two largest private placements in european biotech this year

NL     FR

01/06/2006
ABLYNX STRENGTHENS MANAGEMENT TEAM - EVA-LOTTA ALLAN JOINS AS CHIEF BUSINESS OFFICER

18/05/2006
ABLYNX appoints wim ottevaere as cfo

10/04/2006
ABLYNX and procter & gamble extend nanobody™ drug discovery and development agreement to metabolic targets

27/03/2006
ABLYNX appoints edwin moses as ceo

14/03/2006
ABLYNX REVEALS POWER OF NANOCLONe™ -  a high throughput method for isolating high potent antibody-derived therapeutic proteins (nanobodies™)

09/02/2006
ABLYNX announces research collaboration with kirin brewery
> FOR JAPANESE VERSION CLICK HERE

18/01/2006
ABLYNX ANNOUNCES PHARMA ALLIANCE TO DEVELOP THERAPEUTIC NANOBODIES™

11/01/2006
ABLYNX ANNOUNCES COLLABORATION WITH CENTOCOR RESEARCH AND DEVELOPMENT, INC.

Press releases

News archive

Email alerts

If you would like to receive updates on the company news, please
click here